Recent reports depict a multifaceted picture of
The Clorox Company (NYSE: CLX), an institutional favorite with 81% ownership. Perception of its performance varies, with some praising its significant
Return On Equity of 59%, constant
dividend payments, and robust
financial results, while others point to underperformance in comparison to the market. A central pillar of recent strategy includes
strengthening global supply chain ethics and commitments to sustainable action, demonstrated by its partnership with
M2030 to lower emissions. Clorox is also pushing
diversity and
inclusion initiatives to new standards, paving the way in corporate allyship. Additionally, consistent earnings and dividends have led many to consider it an attractive investment option. Other recent activities include the divestiture of its
Better Health VMS business, fresh board appointments, and an Earnings and Sales beat of FY25 estimates. However, some reports suggest a 'Reduce' consensus amongst analysts, mirroring a mixed sentiment amongst stakeholders.
Clorox Company CLX News Analytics from Fri, 09 Feb 2024 17:17:19 GMT to Thu, 26 Dec 2024 16:38:05 GMT -
Rating 3
- Innovation 5
- Information 6
- Rumor -7
